Italian AAV biotech closes $65M Series A; GSK's Jemperli nabs priority review in endometrial cancer
AAVantgarde, a Milan-based AAV biotech, has closed a €61 million ($65.1 million) Series A round.
The biotech currently has two AAV platforms, one using DNA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
